In a study, systematic biopsy detected clinically significant prostate cancer in only 3% of men with negative findings on multiparametic MRI.
Findings from 2 new studies could enable more informed patient counseling about choice of therapy.
Researchers found no evidence of worse cancer outcomes with nerve-sparing surgery.
A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).
At 6 months of treatment, bone imaging showed stable disease in 94% of patients with available data, study finds.
In multiparametric magnetic resonance imaging, rectal distension have a negative effect on T2-weighted and diffusion-weighted images.
Men with Gleason score 3 + 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 + 3 at 3 years.
Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.
In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.
Cancer-specific mortality rates dropped from 72.8% in 1995 to 55.8% in 2011, according to a Danish study.
Researchers compared targeted prostate biopsy based on biparametric magnetic resonance imaging with standard 12-core systematic biopsy.
Cancer mortality decreased by 20.1% between 1980 and 2014, from 240.2 to 192.0 deaths per 100 000 population.
Combined treatment for recurrent prostate cancer after radical prostatectomy results in decreased long-term all-cause and cancer-specific mortality.
For individual urologists, the probability of using observation for low-risk disease ranged widely from 5.1% to 71.2%.
Targeted biopsy should be considered for grade 4-5 lesions on the Likert scale, researchers say.
Higher death rates found in cancers not related to smoking, carcinoma of the colorectum, prostate, pancreas, oesophagus, and leukemia.
The results suggest that hyperinsulinemia may be a risk factor for prostate cancer.
The median OS differed by race, with superior OS observed among Asian men than among men of other races.
Using imaging to triage men with elevated PSA might avoid a quarter of unnecessary biopsies, according to a study.
No benefit of autologous urethral sling placement at robotic assisted radical prostatectomy on early return of continence at 6 months.
Benign prostatic hyperplasia is more likely to develop among men with larger waist circumference and body mass index and higher leptin levels.
The investigators found that the cancer mortality rate hit its peak in 1991, before beginning a steady slide of roughly 1.5% per year among both men and women through 2014.
The proportions of skeletal-related events did not differ significantly between the every 4-week dosing group vs the every 12-week dosing group of bone metastases patients.
Prostate atrophy in more cores also was associated with lower risks of low- and high-grade disease.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)